Poster Presentation: From Screening to Translation: Porsolt's Integrated Approach to Seizure Research
24 Jun 2024
Salon B
Preclinical
)
- Developing antiepileptic drugs remains a challenging and expensive process due to the complex nature of seizure generation. Putative compounds require screening in a cascade of preclinical models which often fail to adequately address pharmacoresistance and seizure co-morbidities.
- Porsolt offers a comprehensive suite of invitro, ex vivo and in vivo preclinical models to address the challenges of throughput, time and cost associated with screening, as well as complex translatable models for later-stage evaluation. We will present an overview of our comprehensive seizure screening package including our new rapid in vivo package SeizureScan by PorsoltTM.
